The company uses its proprietary development platform Humabody to develop novel therapies which is claims have "superior biophysical properties".
The company's pipeline is led by CB307, a novel bispecific tumour-targeted T-cell engager for the selective activation of tumour-specific T-cells exclusively within the tumour microenvironment, thereby avoiding systemic toxicity.
Investors in Crescendo include Astellas and Takeda as well as VC firms such as Quan Capital.
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze